Author: admin
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Sanofi
a French société anonyme with a registered share capital of 2,526,245,442 €
Registered office : 46, avenue de la Grande Armée – 75017 Paris – France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
| Date |
Total number of |
Number of real voting rights (excluding treasury shares) |
Theoretical number of voting rights (including treasury shares)* |
| December 31, 2024 | 1,263,122,721 | 1,413,130,110 | 1,422,661,191 |
* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi under « Regulated Information in France »:
https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/
| Investor Relations Department e-mail: investor.relations@sanofi.com |
Attachment
Đề xuất
Nebu Ease Portable Nebulizer Claims Evaluated: 2026 Consumer Research Report on Mesh Nebulizer Technology, Respiratory Comfort Features, and What Buyers Should Verify
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
TrimRx Telehealth Weight Loss Platform Examined in 2026 Consumer Research Report on GLP-1 Medication Access, Pricing Transparency and Safety Considerations
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference